By
Drug Target Review2026-01-15T10:10:53
Researchers have shown that changing the molecular structure of NK1 receptor antagonists may restore antidepressant effects after decades of failed trials.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2024-05-07T13:11:19
Sponsored by BellBrook Labs
2023-05-18T10:39:07
Sponsored by BPS Bioscience
2025-11-13T14:00:00
Sponsored by Cell Signaling Technology
2023-04-12T15:28:08
Sponsored by nanoComposix
2023-02-02T11:05:15
Sponsored by Cell Signaling Technology
2024-01-26T13:22:42
Sponsored by bit.bio
Site powered by Webvision Cloud